secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001077183-25-000074
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q1 revenue up 8% to $168M; adjusted EBITDA turns positive at $7M
----------------------------------------------------------------------------

- Consolidated revenue $168M (+8% YoY); net loss improved 4% to $26M.
- Adjusted EBITDA $7M vs $3M prior year, up 102%.
- Revenue per clinical test $459 (+3%).
- Revised FY2025 guidance: revenue $747-759M, adj. EBITDA $55-58M.
- Pathline acquisition adds $12-14M expected revenue to 2025 guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000074/0001077183-25-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000074/neo-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001077183-25-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer